Table 2.

Association of HIV and HIV/HCV infection with flow-mediated dilatation, carotid intima-media thickness, and circulating levels of cell adhesion molecules

Variable	Mean difference in log brachial artery FMD, % (95% CI)	P	Mean difference in log carotid IMT, mm (95% CI)	P	Mean difference in log sICAM-1, ηg/mL (95% CI)	P	Mean difference in log sVCAM-1, ηg/mL (95% CI)	P
HIV/HCV vs. HIV
Unadjusted	0.10 (-0.18-0.38)	0.47	-0.05 (-0.11-0.017)	0.15	0.36 (0.22-0.50)	< 0.001	0.23 (-0.10-0.55)	0.01
Adjusted	0.17 (-0.33-0.68)	0.501	0.05 (-0.05-0.16)	0.273	0.39 (0.14-0.64)	0.0023	0.22 (0.05-0.39)	0.173
HIV/HCV vs. HIV (patients with VL < 50 c/mL)2
Unadjusted	0.009 (-0.33-0.34)	0.96	-0.08 (-0.16-0.003)	0.06	0.33 (0.14-0.52)	0.001	0.17 (-0.06-0.40)	0.14
Adjusted	0.23 (-0.45-0.90)	0.471	0.014 (-0.13-0.16)	0.243	0.55 (0.19-0.90)	0.0033	0.21 (-0.28-0.69)	0.253

¹Adjusted for baseline brachial artery diameter, age, sex, C CDC category, intravenous drug use, men who have sex with men, current protease inhibitor use, lipid-lowering therapy, hypertension, diabetes, smoking, lipodystrophy, systolic blood pressure, fasting total cholesterol and LDL-cholesterol, APRI and FIB-4.

²N = 134

³Adjusted for sex, C CDC category, intravenous drug use, men who have sex with men, current protease inhibitor use, lipid-lowering therapy, smoking, systolic blood pressure, fasting total cholesterol and LDL-cholesterol, APRI and FIB-4.

FMD, flow-mediated dilatation; IMT, intima-media thickness; HCV, hepatitis C virus; CI, confidence interval